Treatment with human complement factor H rapidly reverses renal complement deposition in factor H-deficient mice

Area of Science:

• Immunology
• Nephrology
• Complement System Biology

Background:

• Complete deficiency of complement factor H (CFH) leads to dense deposit disease and atypical hemolytic uremic syndrome.
• CFH regulates the alternative complement pathway; its absence causes uncontrolled C3 activation and secondary C3 deficiency.
• Plasma infusion is a treatment for CFH deficiency-related renal disease but has risks like volume overload.

Purpose of the Study:

• To investigate the efficacy of purified human CFH (hCFH) in a mouse model of CFH deficiency.
• To assess the impact of hCFH treatment on C3 levels and renal pathology in Cfh-gene knockout mice.

Main Methods:

• Utilized Cfh-gene knockout mice that spontaneously develop C3 deficiency and renal abnormalities mimicking dense deposit disease.
• Administered purified human CFH (hCFH) to the knockout mice.
• Monitored plasma C3 levels and glomerular basement membrane C3 deposition.

Main Results:

• hCFH treatment rapidly normalized plasma C3 levels in the knockout mice.
• Glomerular basement membrane C3 deposition was resolved following hCFH administration.
• Long-term treatment was limited by the development of an immune response against hCFH.

Conclusions:

• Purified human CFH (hCFH) effectively corrects C3 deficiency and renal pathology in a mouse model of CFH deficiency.
• hCFH shows promise as an alternative to plasma infusions for treating CFH deficiency-related renal diseases.
• Further research is needed to address the immunogenicity of hCFH for sustained therapeutic use.